Suchergebnisse - "Scheible, Holger"

PubPharm (23)

1

Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective

enthalten in: Xenobiotica; the fate of foreign compounds in biological systems | 2023

von Scheible, H. | Schieferstein, H. | Schmidt, R. | +10

2

Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor : Mass balance, elimination route, and metabolism in healthy participants

enthalten in: Clinical and translational science | 2021

von Scheible, H. | Dyroff, M. | Seithel-Keuth, A. | +8

3

Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor : Mass balance, elimination route, and metabolism in healthy participants

enthalten in: Clinical and Translational Science | 2021

von Scheible, H. | Dyroff, M. | Seithel‐Keuth, A. | +8

4

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

enthalten in: Investigational new drugs | 2020

von Johne, A. | Scheible, H. | Becker, A. | +3

5

Insights into Praziquantel Metabolism and Potential Enantiomeric Cytochrome P450-Mediated Drug-Drug Interaction

enthalten in: Drug metabolism and disposition: the biological fate of chemicals | 2020

von Vendrell-Navarro, G. | Scheible, H. | Lignet, F. | +6

6

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

enthalten in: Investigational new drugs | 2020

von Johne, A. | Scheible, H. | Becker, A. | +3

7

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

enthalten in: Investigational new drugs | 2020

von Johne, A. | Scheible, H. | Becker, A. | +3

8

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

enthalten in: Investigational new drugs | 2020

von Johne, A. | Scheible, H. | Becker, A. | +3

9

A Decade in the MIST : Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory Guidance

enthalten in: Drug metabolism and disposition: the biological fate of chemicals | 2018

von Schadt, S. | Bister, B. | Chowdhury, S. | +16

10

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors

enthalten in: Drug metabolism and disposition: the biological fate of chemicals | 2017

von Scheible, H. | Kraetzer, F. | Marx, A. | +2